Our science is focused on an area of high unmet need

Our lead program, BVX001, is focused on Acute Myeloid leukaemia ("AML"), one of the most aggressive forms of blood cancer.
5 Year Survival Rate in >65s
Acute Myeloid Leukaemia
5%
Our Science

The next phase in targeted cancer therapy

Gen 1
Naked mAb
Gen 2
Antibody Drug Conjugate
(Toxin-conjugated mAb)
Gen 3
Bispecifics, CAR-T
Bi-Cygni® Therapeutics
  • Tumour Selective
  • Wider Therapeutic Window
  • Increased Potency
  • More Accessible Targets

Engineered to target the cancer,
not the patient

BiVictriX is building a novel pipeline of next generation therapeutics that have superior cancer selectivity. By significantly reducing harmful side-effects, we aim to vastly improve the safe dose of therapy patients can withstand; improving the overall effectiveness of the treatment at eradicating the cancer.

Our approach relies on utilising our proprietary library of ‘cancer-specific twin antigen fingerprints’ which are uniquely expressed on the cancer, allowing them to be targeted while leaving healthy cells alone.

By applying this science, we created our Bi-Cygni® therapeutics

Bi-Cygni®

Modulated Binding Arms
=
Reduce Binding to Healthy Cells
Healthy Cell
Single Binding Event on Healthy Cell
=
Limited Activity on Healthy Cells
Cancer Cell
Dual Binding Event on Cancer Cell
=
Maximum Cell Death on Cancer Cells

Significant benefits offered by
Bi-Cygni® therapeutics

Significantly Reduced Toxicity Enables Higher Dosing and Greater Efficacy
Superior Potency Achieved Through Targeting Dual Antigens
Reduced Toxicity Expands Options for Combinatorial Therapies
Expands the Universe of Potential Drug Targets
Highly Adaptable Across Solid/Liquid Cancers, Not Reliant on Tumour Microenvironment
Effective Across Both High and Low Expressing Tumours
newsletter

Contact BiVictriX

Please submit the form below and we shall be in touch
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.